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ABSTRACT
Liposomes are lipid particles formed by self-aggregated phospholipids. They are
clinically used both as delivery vectors and immune adjuvants to treat many human
infectious and cancerous diseases. However, how liposomes interact with host immune
system remains poorly understood. Particularly, little is known about whether an innate
immune receptor exists to sense liposomes. I hypothesize that liposomes activate NLRP3
inflammasome in macrophages, which results in the release of interleukin 1β (IL-1β), a
proinflammatory cytokine that plays a key role in innate and adaptive immune responses.
To test my hypothesis, I will determine the ability of inducing IL-1β secretion
from macrophages by differentially charged liposomes (i.e. cationic, neutral or anionc
liposomes). Furthermore, I will also test whether the intact NLRP3 inflammasome
machinery is required for liposomes-induced IL-1β secretion.

Notably, similar to

liposomes, accumulating evidence has indicated that exposure to other particulates, such
as crystals, can also activate the NLRP3 inflammasome in phagocytes. To delineate the
molecular mechanism by which particulates (liposomes/crystals) activate the NLRP3
inflammasome, I further hypothesize that particulates induce oxidative stress in
macrophages resulting in the production of mitochondrial reactive oxygen species (ROS).
Accumulation of ROS can then induce calcium influx via the transient receptor potential
melastatin 2 (TRPM2) ion channel, which results in the drastic increase of intracellular
calcium concentration. The change in the ionic environment would create a favorable
xv

condition for activation of the NLRP3 inflammasome. To test this, I plan to use
combinations of chemical and genetic approaches. First, I will determine whether
liposomes can induce mitochondrial ROS production and subsequent ROS-dependent
calcium influx via TRPM2 in vitro. Next, by taking advantage of the TRPM2 gene
knockout mice, I will further determine if genetic ablation of TRPM2 could impair
liposomes/crystals-induce NLRP3 inflammasome activation both in vitro and in vivo.
Lastly, because IL-1β-IL-1 receptor signaling axis is critical for inducing humoral
immune responses, I want to test if blocking this signaling pathway would affect
liposomal adjuvant effect in vivo. Briefly, I will determine if, in comparison with wildtype animals, IL-1RI deficient mice would have any defect in mounting target-antigen
specific antibody responses. Taken together, this project will not only identify the
previously unknown innate immune sensor for liposomes, but also provide novel insights
of the molecular mechanism underlying particle-induced NLRP3 inflammasome
activation.

xvi

CHAPTER 1
INTRODUCTION
LIPOSOMES
Liposomes are lipid particles that are formed by self-aggregated phospholipids
(Allison and Gregoriadis, 1974; Christensen et al., 2007; Slingerland et al., 2012). The
lipids contain a nonpolar portion, typically consisting of fatty acid chains, and a polar
portion, typically consisting of a phosphate group and/or tertiary ammonium salts(Allison
and Gregoriadis, 1974; Miller et al., 1998; Perrie et al., 2003; Slingerland et al., 2012;
Vyas and Khatri, 2007). Based on the different charge of the polar region, liposomes can
be further subgrouped into positively charged (cationic), negatively charged (anionic) and
neutral liposomes (Christensen et al., 2007; Perrie et al., 2003; Slingerland et al., 2012;
Vyas and Khatri, 2007). A large panel of phospholipids can be made into liposomes.
Liposomes are useful tools that can be clinically used to treat human diseases. They can
be used as drug delivery vector/vesicle in anti-cancer therapy, and they are also very
important immune adjuvant because they possess strong immunoactivating properties
(Allison and Gregoriadis, 1974; Christensen et al., 2007; Slingerland et al., 2012).
Liposomes are considered as one of the next-generation delivery vectors that are
superior to many conventional therapeutic vectors for in vivo drug-delivery purpose
because the composition and structure of liposomes are highly manipulable (Allison and
Gregoriadis, 1974; Christensen et al., 2007; Slingerland et al., 2012). For instance, certain
1

2
molecules can be directly incorporated into the lipid-bilayer of liposomes or
anchored/attached covalently to the lipids(Christensen et al., 2007; Slingerland et al.,
2012; Vyas and Khatri, 2007; Walker et al., 1992). This will maximize the amount of
drugs carried by delivery vectors and ensure optimal drug efficacy. The ease of attaching
molecules onto the lipid shell is also helpful for target-cell delivery purpose, especially in
anti-cancer

therapy

where

cancer

cell-directed

drug

delivery

is

highly

desirable(Slingerland et al., 2012). Additionally, in comparison with other nextgeneration delivery vectors, such as synthetic polymeric nanoparticles, liposomes can be
easily made into multilamellar liposome, where multiple layers of lipids within the single
liposomes can trap more abundant drugs to ensure gradual and constant release of
therapeutic agents entrapped within each layer.(Zucker et al., 2009) It has been shown
that utilization of multilamellar liposome can substantially improve the anti-cancer
therapeutic efficacy(Pagano, 1978; Pagano and Weinstein, 1978; Satish and Surolia, 2002;
Segota and Tezak, 2006).
From an immunologic point of view, liposomes are also ideal immune adjuvant
because they are more potent than the conventional adjuvant, such as alum, at amplifying
the adaptive immune responses against co-administered antigens(Allison and
Gregoriadis, 1974; Christensen et al., 2007). Interestingly, it appears that the chemical
properties of lipids largely determine the immunologic use of liposomes. Particularly, the
surface charge of liposomes has a major influence on the differential ability to activate
the immune system(Allison and Gregoriadis, 1974; Christensen et al., 2007). In contrast
to the neutral ones, charged liposomes (either cationic or anionic liposomes) are more
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commonly used as immune adjuvants because they seem to possess stronger ability to
facilitate the optimal induction of antigen-specific immunity. For instance, the DOTAP
liposomes, DC-Chol liposomes, and DDA liposomes are all ideal immune adjuvants and
they have been shown to be able to significantly amplify antigen-specific immunity. In
contrast to charged liposomes, the neutral ones are week adjuvants(Allison and
Gregoriadis, 1974; Christensen et al., 2007).
DOTAP liposome is one example of cationic liposomes that can be used as
immune adjuvants. The co-immunization with target protein/peptide with DOTAP
liposomes can elicit CD8+ T cell responses with increased cytolytic T cell activity(Cui et
al., 2005; Walker et al., 1992). Previous studies have suggested that treatment of DOTAP
liposomes can upregulate co-stimulatory molecules (e.g. CD80/86) in antigen presenting
cells to facilitate innate immune cell maturation(Satish and Surolia, 2002; Vangasseri et
al., 2006). Moreover, DOTAP liposomes are also capable of activating MAPK in
dendritic cells (DCs), which might play a role in directing downstream cytokine and
chemokine expression(Yan et al., 2007).
DC-Chol liposomes are another type of cationic liposomes that can generate a
balanced Th1/Th2 response in several animal models(Brunel et al., 1999; Gao and
Huang, 1991; Sanchez et al., 2001). It has been shown that the antibody responses against
human inactivated influenza vaccine can be enhanced if DC-Chol liposomes were
formulated into the vaccine(Guy et al., 2001). DC-Chol liposomes are also effective
mucosal adjuvant and were able to upregulate CCL20 expression in epithelial cells from
both vagina and uterus(Hattori et al., 2004). Furthermore, the combination of DC-Chol

4
liposomes with TLR ligands (such as zymosan, a TLR2 agonist) has been shown to
induce maturation of DCs and Langerhans’ cells(Cremel et al., 2006).
DDA is another cationic lipid that can form liposomes when heated to above its
gel-liquid phase transition temperature (470C)(Davidsen et al., 2005; Feitosa et al., 2000).
It has been shown that immunization of mice with hapten-carrier complexes and DDA
liposomes generated hapten-specific delayed-hypersensitivity, suggesting the DDA
liposomes are able to induce a cell-mediated immunity(Dailey and Hunter, 1974; Snippe
et al., 1977). Furthermore, DDA liposomes have also been used as immune adjuvant in
various vaccine formulations against viruses, bacteria and even tumors(Katz et al., 1996;
Klinguer-Hamour et al., 2002; Kraaijeveld et al., 1983; Lindblad et al., 1997; Prager and
Gordon, 1978). Notably, DDA has been shown to be a safe immune adjuvant that does
not appear to have side effect as seen by other immune adjuvants in humans(Hilgers and
Snippe, 1992; Stanfield et al., 1973; Veronesi et al., 1970).
Although certain charged liposomes are strong immune adjuvants themselves,
they can also be used in combination with other immumodulators, such as pathogenassociated molecular patterns (PAMPs) molecules (e.g. TLR agonists) or self dangerassociated

molecular

patterns

(DAMPs)

molecules

(e.g.

HMGB1,

dsRNA,

ATP)(Christensen et al., 2007). It has been shown that such combinational approaches
can further enhance the adjuvanticity of charged liposomes and be helpful at inducing a
desirable Th1/Th2 biased or balanced immune responses, respectively(Christensen et al.,
2007; Klinguer-Hamour et al., 2002; Pagano, 1978).

5
In summary, liposomes are both efficient drug-delivery vectors and powerful
immune adjuvants. Their clinical use has been proven to be beneficial for the treatment of
many human infectious and cancerous diseases(Allison and Gregoriadis, 1974;
Christensen et al., 2007; Pagano, 1978). However, little is known about how liposomes
interact with the host immune system. Also, the mechanism underlying the apparently
different outcome of such interaction remains elusive. Therefore, it is of utmost
importance to study how the host immune system recognizes liposomes and subsequent
immune responses after the initial recognition. Furthermore, the better understanding of
how different liposomes interact with host immune system will also help to optimize the
clinical use of liposomes: in the context of vaccine against infectious diseases, the
liposomes that are more potent of activating the immune system may be more preferable,
whereas the ones that are week immune activators may be more suitable for anti-cancer
drug delivery purpose.

NOD-LIKE RECEPTORS
Nod like receptors (NLRs) are a group of newly identified innate immune
receptors or pathogen recognition receptors (PRRs)(Gross et al., 2011; Ogura et al., 2006;
Schroder and Tschopp, 2010). The NLR family members are characterized based upon
their signature domains with each member protein, such as the leucine-rich repeats
(LRRs), the nucleotide-binding and oligomerization (NACHT) domain, the caspase
recruitment domain (CARD) or pyrin (PYD) domain(Gross et al., 2011; Schroder and
Tschopp, 2010). The NACHT domain is the only universal domain for all members of
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NLRs and it mediates the activation of NLRs in response to their stimuli. Based upon
phylogenetic analysis, NLRs can be further divided into 3 subfamilies; NLRPs (NLRP114), NODs (NOD1-2, NOD3/NLRC3, NOD4/NLRC5, NOD5/NLRX1, CIITA), and
IPAFs (IPAF/NLRC4 and NAIP)(Gross et al., 2011; Ogura et al., 2006; Schroder and
Tschopp, 2010).
So far, there are 22 NLRs members identified in human and even more in mouse
due to genetic expansion. Like other PRRs, such as Toll-like receptors, the NLRs
function to sense the presence of pathogens, foreign intruders, and even “self-danger”
signals(Gross et al., 2011; Ogura et al., 2006; Schroder and Tschopp, 2010). For instance,
Nlrp1 recognizes anthrax lethal toxin whereas Nlrc4 detects bacterial flagellin and
components of bacterial type III and IV secretion systems(Gross et al., 2011; Ogura et al.,
2006; Schroder and Tschopp, 2010). NOD1 and NOD2 recognize bacterial cell wall
breakdowns (mesodiaminopimelic acid and muramyl dipeptide, respectively)(Gross et
al., 2011; Ogura et al., 2006; Schroder and Tschopp, 2010). NLRP3 appears to recognize
the cytosolic changes within innate immune cells (e.g. macrophages) because it can sense
a large diverse pool of activators that are structurally and functionally unrelated to each
other(Bulua et al., 2011; Gross et al., 2011; Kepp et al., 2011; Naik and Dixit, 2011;
Ogura et al., 2006; Schroder and Tschopp, 2010; Tschopp, 2011; West et al., 2011).
Although much progress has been made during the last decade, in contrast to TLRs--the
function of which have been extensively studies during the last two decades, little is
known regarding the specificity and function of most NLRs.
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Upon activation, some of the NLRs forms a large cytosolic protein aggregates,
termed “inflammasomes”(Gross et al., 2011; Ogura et al., 2006; Schroder and Tschopp,
2010). It functions to induce caspase-1 autocleavage and activation, which mediates the
proteolytic processing of immature IL-1β into its mature and bioactive form.
Additionally, active caspase-1 has also been shown to direct pyroptosis, a specialized cell
death that is different from apoptosis or necrosis(Kepp et al., 2010; Miao et al., 2011;
Schroder and Tschopp, 2010; Strowig et al., 2012). Although some NLRs can form
inflammasomes when they are activated by their cognate ligands/stimuli, the composition
of inflammasomes is not identical. For instance, NLRP3 inflammasome formation
requires NLRP3, ASC and Caspase-1, whereas some other NLRs, such as NLRP1, do not
involve ASC for assembly(Gross et al., 2011; Ogura et al., 2006; Schroder and Tschopp,
2010).
THE NLRP3 INFLAMMASOME
The NLRP3 inflammasome in health and disease
The NLRP3 inflammasome forms by NLRP3, ASC and Caspase-1. Its activation
is unique among all PRRs because a large pool of diverse stimuli are known to induce the
formation of NLRP3 inflammasome(Gross et al., 2011; Jin and Flavell, 2010; Kepp et al.,
2011; Ogura et al., 2006; Schroder and Tschopp, 2010; Tschopp, 2011). Notably, these
activators are structurally and functionally unrelated, which makes the activation
mechanism of NLRP3 inflammasome more mysterious.
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So far, a number of studies have identified more than 30 activators of the NLRP3
inflammasome, and the list is still growing (see Table 1.1)(Gross et al., 2011; Jin and
Flavell, 2010; Kepp et al., 2011; Tschopp, 2011). The activators of NLRP3
inflammasome range from pathogenic bacteria and viruses (e.g. listeria, adenovirus), to
environmental insults (e.g. silica crystals) and self-danger signals (e.g. ATP, uric acid
crystals). Although these activators differ significantly in their structure, function, and
clinical relevance, it appears that they can transmit common signal(s), via a not yet
completely understood mechanism, that ultimately drives the assembly of the NLRP3
inflammasome and leads to the maturation and release of powerful proinflammatory
cytokines, such as IL-1β and IL-18(Kepp et al., 2011; Schroder and Tschopp, 2010; Zhou
et al., 2011).
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Table 1.1. List of activators of NLRP3 inflammasome
Activator class
Environmental insults

Activators
Ultraviolet light
Asbestos crystals
Silica crystals
Skin irritants

Endogenous danger signals

ATP
Uric acid crystals
Glucose
Amyloid β
Hyaluronan

Immune adjuvant

Alum
Complete Freunds adjuvant

Pathogen and its associated molecules

Listeria monocytogenes
Influenza virus
Adenovirus
Sendai virus
Candida albicans
Saccharomyces cerevisiae
Hemozoin
Bacterial pore-forming toxin
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Synthetic materials

Titanium particles
Polymeric nanoparticles
PLGA particles
Gold nanoshell particles

Mutations in the NLRP3 inflammasome machinery, namely the Nlrp3 gene, are
frequently associated with many human diseases(Kingsbury et al., 2011; Strowig et al.,
2012; Vandanmagsar et al., 2011; Zaki et al., 2011). This is due to the fact that the
dysregulated activation of the NLRP3 inflammasome triggers the release of
proinflammatory cytokine, and the elevation of systemic and local concentrations of these
cytokines are known to mediate undesirable inflammation associated with many
devastating autoinflammatory diseases (see Table 1.2).
Besides genetic variance, self metabolic products or environmental insults are
also capable of activating the NLRP3 inflammasome(Strowig et al., 2012). For instance,
the accumulation of uric acid—a metabolic product—at joints can induce chronic local
inflammation and pain, the symptom of which is usually referred as “gouty arthritis” or
“gout”(Kingsbury et al., 2011; Martinon et al., 2006; Punzi et al., 2012; Rock et al., 2012;
Smith et al., 2011). Similar to uric acid, silica crystal is one of the major causal agents for
occupational health problems, such as silicosis. The inhalation of silica particles activates
the NLRP3 inflammasome in the airway and lung, sensitizes the epithelial cells and
induces chronic inflammation in the upper respiratory tract. If left untreated, many
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workers exposed to silica particles may eventually develop pulmonary fibrosis(Cassel et
al., 2008; Dostert et al., 2008; Hornung et al., 2008).
Accumulating evidence has indicated that many other metabolic products, which
are of non-crystalline nature, also activate the NLRP3 inflammasome to initiate
inflammatory responses that significantly contribute to the manifest of clinical
problems(Strowig et al., 2012). For instance, the activation of NLRP3 inflammasome by
human islet polypeptide has been shown to play a major role in facilitating the
development of type II diabetes(Masters et al., 2010). Moreover, the NLRP3
inflammasome has been identified as the missing link that connects high fat containing
diet with obesity and insulin resistance. Saturated fatty acid, which is highly enriched in
high-fat diet, is the trigger for NLRP3 inflammasome activation. Consequently, released
IL-1β will bind to IL-1R that can interfere with insulin signaling(Wen et al., 2011).
In conclusion, solid evidence has suggested a critical role of NLRP3
inflammasome in a number of autoinflammatory or metabolic diseases. Thus, it is of
utmost importance to further investigate the activation mechanism of NLRP3 in the
context of various human diseases.
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Table 1.2. List of human diseases associated with dysregulated NLRP3
inflammasome activation
Diseases associated with dysregulated

Activators

NLRP3 inflammasome activation
Gout

Uric acid crystals

Asbestosis

Asbestos crystals

Silicosis

Silica crystals

Atherosclerosis

Cholesterol crystals

Alzheimer’s disease

Amyloid β

Parkinson’s disease

α-synuclein

Type II diabetes

Fatty acid and/or self-danger signals

Cancer

Self-danger signals (e.g. ATP, uric acid)

Obesity

Fatty acid and/or self-danger signals

Pathogen-infection

Viruses,

bacteria,

and/or

pathogen

associated molecules
Geographic atrophy

Alu RNA

Allergy

Environmental

insults

(e.g.

allergic

substances)

Activation mechanisms of the NLRP3 inflammasome
Although many activators of NLRP3 have been identified in the last decades, the
precise molecular mechanism that leads to the activation of the NLRP3 inflammasome
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remains elusive. This is at least in part due to the lack of a universal pathway that is
responsible for NLRP3 inflammasome activation by all its stimuli. However, at least
three models have been proposed for activating the NLRP3 inflammasome(Kepp et al.,
2011; Schroder and Tschopp, 2010; Tschopp and Schroder, 2010) (see Figure 1.1.).

Figure 1.1: Mechanisms of NLRP3 inflammasome activation. Three models have
been proposed for NLRP3 inflammasome activation: the first model involves potassium
efflux. Activators of NLRP3 inflammasome, such as ATP and crystals, can induce
potassium depletion in the cytoplasm, a required step for NLRP3 inflammasome
activation; the second model involves rupture of lysosome and subsequent release of
lysosomal contents, such as cathepsins. This will somehow lead to the assembly of
NLRP3 inflammasome via an unidentified mechanism; the last model involves oxidative
stress, in which the mitochondria is damaged upon stimulation of NLRP3 inflammasome
activators. This will lead to the accumulation of mitochondrial reactive oxygen species
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(ROS), that can somehow transmit signals that directs the assembly of NLRP3
inflammasome. Although a large body of evidence has supported these models
respectively, it appears that a unifying model that can incorporate all three mechanisms
has yet to be further identified and explored.

The first model involves potassium. In 2007, Tschopp and colleagues first
demonstrated that the blockade of potassium efflux could inhibit NLRP3 inflammasome
activation(Petrilli et al., 2007). Later studies have also confirmed that potassium efflux is
required NLRP3 inflammasome activation by most, if not all activators(Cassel et al.,
2008; Eisenbarth et al., 2008; Gross et al., 2011). Although these data unify a critical role
of reducing cytosolic potassium level in driving the assembly of the NLRP3
inflammasome, the mechanism involved remains largely unknown.
The second model for NLRP3 inflammasome activation involves lysosome
rupture and subsequent release of lysosomal contents, which somehow induce the
activation of the NLRP3 inflammasome. This model seems to apply to most particulate
activators because it is conceivable that these large particles may induce phagocytic stress
in macrophages, leading to the breakage of lysosome membrane and passive release of
lysosomal contents to the cytosol. Latz and colleagues are the first group to identify the
lysosomal cathepsin B, a cysteine protease, as a critical player for crystals-induced
inflammasome activation(Duewell et al., 2010; Halle et al., 2008; Hornung et al., 2008).
They proposed a “lysosome-cathepsin B” model in which the phagocytosed crystals are
believed to trigger cathepsin B release from phagolysosome and induce NLRP3
inflammasome assembly and activation. However, their results were solely based on a
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cathepsin B inhibitor, CA-074-Me. Consequently, this model was recently challenged
based upon the fact the genetic ablation of cathepsin B had little effect on NLRP3
inflammasome activation(Dostert et al., 2009). It appears that the off-target side effect of
CA-074-Me is likely to interfere with the data interpretation. In addition to cathepsin B,
Latz and colleagues have recently proposed a role for other lysosomal cathepsins, such as
cathepsin L, in driving the NLRP3 inflammasome activation(Duewell et al., 2010).
However, it remains to be further investigated whether multiple cathepsins play a
redundant role in directing NLRP3 inflammasome activation.
The third model involves reactive oxygen species (ROS), which was first brought
up by Tschopp and his colleagues in 2008(Dostert et al., 2008). They initially proposed
that ROS generated by NADPH oxidase (NOX) during phagocytosis of particles. As
ROS are important signaling molecules that can directly or indirectly modify other
cellular components or molecules, Tschopp reasoned that ROS might also play a role in
NLRP3 inflammasome activation. In fact, the blockade of ROS by anti-oxidant prevented
NLRP3 inflammasome activation. However, the “ROS” model was also challenged by
others because knocking down of each individual NOXs or their common subunit did not
significantly affect NLRP3 inflammasome activation(Bauernfeind et al., 2011; Hornung
et al., 2008). In 2011, Tschopp’s group further investigated the source of ROS during
NLRP3 inflammasome activation, and they found that ROS are mainly from
mitochondria, but not NOXs(Zhou et al., 2011). They elegantly showed solid evidence
suggesting that mitochondrial ROS plays a key role in directing the NLRP3
inflammasome activation. Subsequent studies have also found that other contents
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released from mitochondria also play a role in NLRP3 inflammasome activation(Misawa
et al., 2013; Nakahira et al., 2011). For instance, unoxidized mitochondrial DNA
(mtDNA) are shown to activate AIM2 inflammasome which further enhanced the
generation of more mature IL-1β(Nakahira et al., 2011). Additionally, the oxidized
mtDNA is able to bind to NLRP3 to directly induce the assembly of NLRP3
inflammasome(Shimada et al., 2012). These findings clearly suggest that mitochondria
play a critical role in directing the NLRP3 inflammasome activation. Although
mitochondrial ROS is known to signal the assembly of NLRP3 inflammasome, the
mechanism involved remains largely unknown.
OXIDATIVE STRESS AND NLRP3 INFLAMMASOME
Mitochondria regulate NLRP3 inflammasome activation
Mitochondrion is an ancient cellular organelle that provides energy for essentially
all biological processes within the cell. Notably, studies during the last several decades
have clearly suggested additional roles of mitochondria in regulating other
pathophysiological events(Tschopp, 2011). For example, a number of neurodegenerative
diseases, namely Alzheimer’s diseases and Parkinson’s diseases, have been closely linked
to malfunctioned mitochondria. Additionally, mitochondrial contents and related
signaling pathways are key players in shaping the proper immune responses to bacterial
and virus infections. MAVS (mitochondrial anti-viral signaling protein) has been one of
the best examples for this. Solid evidence has indicated that MAVS plays a key role in
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RIG-I like receptor signaling pathway and it regulates antiviral innate immune responses
via directing type I interferon production(Hou et al., 2011; Seth et al., 2005).
Recently, Tschopp and colleagues have revealed a novel role of mitochondria in
regulating the NLRP3 inflammasome activation(Zhou et al., 2011). They found that
blocking of mitochondrial respiratory chain, which results in ROS elevation, could
induce spontaneous NLRP3 inflammasome activation in the complete absence of NLRP3
exogenous agonists. Moreover, the mtDNA released from mitochondria upon NLRP3
agonists stimulation also contributes to the proinflammatory responses(Nakahira et al.,
2011). Similarly, it has been shown that genetic knocking-down of a mitochondrial inner
membrane channel, VDAC (voltage dependent anion channel), attenuates NLRP3
inflammasome activation(Zhou et al., 2011). Later studies have also indicated that the
mitochondrial membrane potential is significantly altered upon stimulation with NLRP3
agonists(Barlan et al., 2011; Zhong et al., 2013). This alternation in membrane potential
seems to perfectly correlate with the dynamics of NLRP3 inflammasome activation.
Nonetheless, it appears that mitochondria can regulate the activation of NLRP3
inflammasome at multiple levels, and the combination of such events ensures the
complete activation of the NLRP3 inflammasome. In summary, mitochondria sense the
cellular abnormality and transmit signals to induce downstream assembly of the NLRP3
inflammasome and proinflammatory cytokine processing and secretion.
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Calcium and NLRP3 inflammasome
Although potassium has been widely accepted as the key player during NLRP3
inflammasome activation(Gross et al., 2011; Schroder and Tschopp, 2010), how cytosolic
potassium depletion facilitates the assembly of NLRP3 inflammasome remains largely
unknown. In addition to potassium, a role of calcium mobilization has been proposed in
NLRP3 inflammasome activation. Horng and her colleagues have shown that blocking
calcium flux was able to inhibit NLRP3 inflammasome activation by many NLRP3
agonists, and they further revealed a role of CHOP transcription factor in directing ATPinduced NLRP3 inflammasome activation(Murakami et al., 2012).
Two recent studies have also indicated that extracellular calcium elevation can be
recognized by the macrophages as a “self-danger” signal that activates the calcium
sensing receptors (CaSR) that can induce an IP3R-mediated calcium mobilization from
ER(Lee et al., 2012; Rossol et al., 2012). This event can, via unknown mechanism,
regulate NLRP3 inflammasome activation by many activators.
Despite the evidence indicating a role of calcium in regulating NLRP3
inflammasome activation, little is known regarding how the calcium mobilization is
triggered and how the calcium would fit into other known models for NLRP3
inflammasome activation. Particularly, because both mitochondrial ROS and calcium are
important for NLRP3 inflammasome activation, how these key players are connected is
unclear. Moreover, the identity of potential calcium channel and how elevated calcium
induces NLRP3 inflammasome assembly remain to be further investigated.
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TRPM2 (TRANSIENT RECEPTOR POTENTIAL MELASTATIN 2) CHANNEL
An overview of the TRPM2 channel
Transient receptor potential (TRP) proteins are comprised of a large family of
cation-permeable ion channels that are homologues of the Drosophila TRP protein(Link
et al., 2010; Sumoza-Toledo and Penner, 2011; Yamamoto et al., 2008). The mammalian
TRP superfamily has 28 members, and can be grouped into six subfamilies: canonical or
classic (C), polycystin (P), vanilloid (V), melastatin(M), mucolipin (ML) and ankyrin (A).
The TRP protein is typically characterized by six-transmembrane domains, with both Nand C-termini oriented toward the cytosolic space. The cation fluxes occur between the
fifth and sixth transmembrane domains. The TRP-melastatin subfamily (TRPM), named
for melastatin (a tumor suppressor), contains 8 family members: TRPM1–TRPM8. Most
TRPM channels (TRPM1–6, and TRPM8) have multiple variants, either as a full-length
protein or a short splicing variant, which might explain the complex biological roles of
TRPMs, such as modulating the function, ion selectivity and cellular localization of these
cation channels. Nonetheless, further study is still needed to delineate the precise function
of each channel variants in different cells.
TRPM2 is non-selective multifunctional cation channel, which is Ca2+
permeable(Takahashi et al., 2011; Yamamoto et al., 2010). It contains the N-terminus
homology domain (MHR), the transmembrane domain (TM) coil-coil domain and Cterminus activation domain (Nudix-like domain, NUDT9-H). The human TRPM2 gene is
located in chromosome 21q22.3, and consists of 32 exons. The human TRPM2 gene
encodes a protein of 1503 amino acids. Slightly different from its human homologue, the
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mouse TRPM2 gene contains 34 exons. The TRPM2 protein comprises six
transmembrane segments, flanked by the intracellular N- and C-termini, with the poreforming channel domain located between the fifth and sixth transmembrane domains.
Although several studies have revealed multiple activators for TRPM2
channel(Takahashi et al., 2011; Yamamoto et al., 2010), such as ADP-ribose
(ADPR)(Sumoza-Toledo and Penner, 2011), cyclic ADP-ribose (cADPR), calcium, and
H2O2, ADPR has been generally accepted as the primary activating/gating agent of
TRPM2 channel. ADPR binds to the NUDT9-H domain on the C-terminus of TRPM2
and is subsequently hydrolyzed to ribose 5-phosphate and AMP, which is most likely due
to the enzymatic activity of the C-terminus of TRPM2. Notably, this enzymatic feature of
TRPM2 has been proposed to provide a negative regulation mechanism for controlling
the opening of TRPM2 because AMP is known to antagonize ADPR-mediated gating of
TRPM2(Sumoza-Toledo and Penner, 2011). Upon binding of TRPM2 gating agents (e.g.
ADPR), TRPM2 channels will transiently open and allow the pass through of a number
of cations, such as Na+, K+ and Ca2+, into the cell. A linear current–voltage relationship,
characterizes TRPM2 currents and TRPM2 has a remarkably long open-time (several
seconds) in comparison with other cationic channels(Rossol et al., 2012; Sumoza-Toledo
and Penner, 2011; Takahashi et al., 2011).
TRPM2 is expressed in many tissues and organs with its highest level seen in
brains(Sumoza-Toledo and Penner, 2011). Due to the unique expression pattern, the role
of TRPM2 has been extensively studied in neurons and more importantly, in the context
of a number of neurodegenerative diseases, such as Alzheimer’s diseases, multiple
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sclerosis, and Parkinson’s disease. Mice deficient in TRPM2 showed significant
protection in animal models of several neurological diseases, suggesting that TRPM2mediated calcium mobilization positively regulates the onsite/progression of such
diseases(Naziroglu, 2011).
Besides its expression in brains, TRPM2 has also been detected in other tissues
such as spleen, bone marrow, heart, liver and lung, and in a number of different cell types
like pancreatic β-cells, endothelial cells, epithelial cells, cardiomyocytes and a panel of
immune cells (e.g. neutrophils, monocytes/macrophages and T cells)(Sumoza-Toledo and
Penner, 2011; Takahashi et al., 2011). However, in contrast to its role in brain neurons
and microglia, the role of TRPM2 in other cells has not yet been largely explored. It is
conceivable that the TRPM2-mediated cation fluxes may presumably play regulatory
roles in shaping the function of many different cells in which TRPM2 is expressed.

TRPM2 channel and oxidative stress
Due to the fact that TRPM2 channel can open under oxidative stress conditions,
much attention has been paid to the role of TRPM2 in sensing the redox change within
the cell(Sumoza-Toledo and Penner, 2011; Takahashi et al., 2011). The generation of
reactive oxygen species (ROS) is a signature event when cells are under oxidative stress
triggered by foreign insults or self-genetic instability. ROS are reactive molecules that are
able to modulate almost all other molecules within the cell, such as lipid, protein, DNA,
and RNA(Bulua et al., 2011; Kepp et al., 2011; Naik and Dixit, 2011; Tschopp, 2011).
Therefore, it has been widely accepted that ROS function as a signaling messenger or
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intermediate to direct downstream events which ultimately regulate/alter the activity of
certain molecule or the function of a cellular organelle.
Recent studies have linked TRPM2 activity with oxidative stress by showing that
gating of TRPM2 channel is frequently associated with oxidative damage in the
cell(Takahashi et al., 2011). This notion is supported by the fact that oxidative stressinduced DNA damage in the nucleus is known to induce the accumulation and release of
abundant free ADPR, which can bind to TRPM2 to induce cationic fluxes(Naziroglu,
2007; Perraud et al., 2003). Additionally, it has also been proposed that the ADPR
released from mitochondria, another source of cellular ADPR, might also contribute to
the TRPM2 opening under oxidative stress, because mitochondria are highly sensitive to
environmental stress which likely to converts such stress signals to oxidative damage in
the cell(Perraud et al., 2005).
From an immunological prospect, TRPM2 is also a critical player in the immune
system. For instance, seminal studies by Mori group have clearly demonstrated the key
role of TRPM2 in mediating oxidative stress (e.g. ROS) induced upregulation of
chemokine expression, which contributes to the aggregation of local proinflammatory
responses(Yamamoto et al., 2008). This is of particular interest in innate immunity
against microbes because several studies have revealed that mice deficient in TRPM2 are
defective in controlling the pathogenesis of bacterial infection. For instance, TRPM2
deficiency has been shown to drastically affect the ability of mouse immune system to
restrict Listeria monocytogenes infection(Knowles et al., 2011). Interestingly enough, as
Listeria monocytogenes are known activator of NLRP3 and AIM2 inflammasomes(Kim
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et al., 2010), we reasoned it would be interesting to investigate the role of TRPM2mediated calcium mobilization in inflammasome activation, especially considering the
fact that calcium is a critical player for regulating inflammasome activity.

CHAPTER 2
RATIONALE AND DISSERTATION OUTLINE
Liposomes are particles consisting of self-aggregated lipids and are commonly
used as effective immune adjuvants and efficient drug delivery vehicles to treat various
infectious and cancerous diseases(Al-Jamal and Kostarelos, 2011; Allison and
Gregoriadis, 1974; Christensen et al., 2007; Slingerland et al., 2012). Although previous
studies have indicated that liposomes can enhance the expression of chemokines, such as
CCL2 and co-stimulatory molecules such as CD80/86 in antigen-presenting cells(Cremel
et al., 2006; Cui et al., 2005; Vangasseri et al., 2006; Yan et al., 2007), little is known
about whether an innate immune receptor exists to sense the presence of liposomes.
During the past decade, a number of studies have demonstrated that particulate
substances such as alum, silica, monosodium urate, and calcium pyrophosphate dihydrate
crystals can induce NLRP3 (Nod-like receptor family, pyrin domain containing 3)
inflammasome activation which mediates the secretion of biologically active IL-1β from
macrophages(Dostert et al., 2008; Eisenbarth et al., 2008; Hornung et al., 2008; Li et al.,
2008; Martinon et al., 2006). Because liposomes are also of particulate in nature, I
hypothesized that the NLRP3 inflammasome may serve as an innate immune sensor for
liposomes.
Although the precise mechanism by which the NLRP3 inflammasome is activated
remains unknown, several stress-related cellular processes, including cytosolic depletion
24
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of potassium, lysosome disruption, mitochondrial damage and intracellular calcium
elevation have been proposed to be involved in activation of this inflammasome(Jin and
Flavell, 2010; Murakami et al., 2012). Mitochondria are an ancient and evolutionarily
conserved cellular organelle that play a key role in regulating the signaling pathways of
pattern recognition receptors (PRRs)(West et al., 2011), including the NLRP3
inflammasome. Upon stimulation with particulate stimuli, mitochondria can transmit
stress signals to alarm the immune system via secondary signaling messengers, such as
mitochondrial reactive oxygen species (ROS) (Kepp et al., 2011; Tschopp, 2011; West et
al., 2011). Blocking ROS generation by mitochondria has been shown to abolish NLRP3
inflammasome activation whereas artificial induction of mitochondrial ROS can
spontaneously induce NLRP3-mediated IL-1β secretion(Nakahira et al., 2011; Zhou et
al., 2011). Although it is clear that mitochondrial ROS play a pivotal role, the precise
mechanism underlying ROS-induced NLRP3 inflammasome activation remains poorly
understood.
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Figure 2.1: Dissertation outline/working model. I hypothesize the charged liposomes,
but not neutral ones, activate the NLRP3 inflammsome to induce bioactive IL-1β
secretion from macrophages. Briefly, upon macrophage uptake of charged liposomes, it
can induce oxidative stress which makes mitochondria under stressed conditions. This
will further lead to the accumulation of mitochondrial reactive oxygen species and
subsequently induce a calcium influx via the plasma membrane TRPM2 channel. The
gating of TRPM2 channel can be achieved by at least two ways, which depends on free
ADP-ribose release from nucleus or direct H2O2 opening of the TRPM2 channel,
respectively. The elevation in intracellular calcium concentration will then create a
preferable ionic environment which favors the assembly of the NLRP3 inflammasome
and subsequent caspase-1 activation, proteolytic processing of pro-IL-1β, and release of
bioactive mature IL-1β. This process will also be accompanied by cytosolic depletion of
potassium (potassium efflux). However, the precise relationship between potassium and
calcium mobilizations in NLRP3 inflammasome activation process needs further
investigation.

CHAPTER 3
MATERIALS AND METHODS
Reagents
1,2-Dioleoyl-3-trimethylammonium-propane
dimethylaminoethane)-carbamoyl]cholesterol
dimethyldioctadecylammonium

(bromide

salt)

(DOTAP),

3β-[N-(N',N'-

hydrochloride

(DC-Chol),

(DDA),

1,2-dioleoyl-sn-glycero-3-

phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2dimyristoyl-sn-glycero-3-phospho-(1'-rac-glycerol)

(DMPG)

and

L-α-

phosphatidylcholine (soy extract) were purchased from Avanti Polar Lipids (Alabaster,
AL). Track-etch polycarbonate membranes (2 µm, 800 nm, 400 nm, 200 nm and 100 nm)
were from Millipore, The Lipex liposomes extruder was from Northern Lipids and other
common lab chemicals and reagents were from Sigma-Aldrich and Fisher Scientific.
Cholesterol, ovalbumin, silica, ATP, phorbol 12-myristate 13-acetate (PMA),
cytochalasin D, uricase, bafilomycin A1, Ca-074-Me, H2O2, rotenone, antimycin and
BAPTA-AM were from Sigma-Aldrich. Ultrapure LPS, zymosan, and poly(dA:dT), and
glibenclamide were from Invivogen. zYVAD-fmk, APDC and DPQ were from Alexis
Biochemicals. DPI was from Calbiochem. Monosodium urate crystals, VAS2870 and
NAC were from Enzo Lifescience. Imject Alum and streptavidin-HRP were from Pierce.
Lipofectamine 2000, MitoSOX and fura-2-AM were from Invitrogen. Calcium free and
calcium containing DMEM media were from US Biologicals. The lactate dehydrogenase
27
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(LDH) assay kit was from Roche. Antibodies used for immunoblotting were as follows:
anti-mouse caspase-1 (sc-514, Santa Cruz Biotechnology), anti-mouse β-actin (sc-1615
HRP, Santa Cruz Biotechnology) and anti-mouse IL-1β (AF-401-NA, R&D systems).
Antibodies used for determining OVA-specific IgG isotypes IgG1 and IgG2b were from
Biolegend, and the antibody for mouse IgG2c was from Bethyl Laboratories.

Liposomes formulations
A total of 16 different liposomes formulations (see Table 3.1) were produced by
Encapsula NanoSciences. The liposomes were made using the dehydration-rehydration
method. The lipids were dissolved in chloroform in a round bottom flask, and the solvent
in the flask was then evaporated using a Büchi (RE-121) rotary evaporator (Flawil,
Switzerland) under a vacuum for 4 hours, resulting in the formation of a thin lipid film.
The thin lipid film was hydrated with deionized water for 2 hours at 37°C and then over
night at 4°C. The milky solution of liposomes was extruded 25 times through an
appropriately sized polycarbonate membrane filter using a Lipex extruder connected to a
high-pressure nitrogen cylinder to produce liposomes of the desired sizes. For example,
liposomes were passed through a 100-nm polycarbonate membrane filter 25 times to
produce 100-nm liposomes.
To formulate ovalbumin-encapsulated liposomes, the thin lipid film was hydrated
with a solution of ovalbumin in deionized water. The liposomes were sized to 400 nm.
The non-encapsulated ovalbumin was separated using 100K dialysis membrane tubing
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(Spectrum Laboratories). The amount of the encapsulated ovalbumin was determined by
BCA assay using a BCA protein assay kit (ThermoFisher Scientific).

Table 3.1 Liposome formulations
Lipid
composition
DOTAP
DOTAP
DOTAP
DOTAP
DOPC
DOPC
DOPC
DOPC
DOTAP:DOPC
DOTAP:DOPC
DOTAP:DOPC
DPPC:DMPG
DC-Cholesterol
DDA
L-α-PC:
Cholesterol
DOTAP-OVA
(OVA
encapsulated)

Lipid Molar percentage

Size (nm)

Concentration (mg/ml)

100
100
100
100
100
100
100
100
50:50
80:20
90:10
70:30
100
100
70:30

100
200
400
800
100
200
400
800
100
100
100
100
100
100
2000

10
10
10
10
10
10
10
10
20
10
10
10
10
10
23

100

400

10 mg/ml of lipid and 2
mg/ml of encapsulated
ovalbumin

Cell culture and stimulation
Human THP-1 cells (ATCC) were grown in RPMI-1640 medium supplemented
with 10% (vol/vol) FBS. THP-1 cells were primed with PMA (100 nM) for 3h, washed
three times and cultured overnight in serum-free DMEM medium. The cells were then
stimulated with either liposomes or crystals for 18h, and the supernatants were collected
for the detection of human IL-1β by ELISA. Bone marrow-derived macrophages
(BMDMs) were generated by culturing the mouse bone marrow cells in the presence of
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20% vol/vol L929 conditional media as previously described(Hornung et al., 2008; Wen
et al., 2011). After pretreatment with ultrapure LPS (100 ng/ml for primary BMDMs and
50 ng/ml for immortalized macrophages) for 16-18h, the BMDMs were stimulated with
ATP for 30min unless otherwise indicated or liposomes, alum, silica, MSU crystals or
H2O2 for 6h. Poly(dA:dT) was transfected into the macrophages using Lipofectamine
2000 (4 µg/ml) according to manufacturer’s instructions. For the experiments using
chemical inhibitors, the inhibitors were added 45 min prior to stimulation with the
NLRP3 inflammasome agonists. The blockade of potassium efflux with a high
concentration of KCl was performed as previously described(Eisenbarth et al., 2008). For
the experiments using calcium-free medium, BMDMs were first primed with LPS for 18h
in calcium-containing DMEM, washed four times with PBS and then cultured in calciumfree DMEM in the presence of inflammasome agonists. Supernatants and cell lysates
were collected for ELISA and immunoblotting analyses. Immortalized murine
macrophages from Nlrp3−/−, Asc−/−, Capase 1−/−, Nlrc4−/−, Cathepsin B−/−, Aim2−/− mice
and their corresponding wild-type control cells were generously provided by Dr.
Katherine Fitzgerald and as previously described(Hornung et al., 2008).

Enzyme-linked immunosorbent assay
Paired (capture and detection) antibodies and standard recombinant proteins for
mouse IL-1β, tumor necrosis factor and IL-6 (from eBioscience) were used to quantify
the cytokine levels in cell culture supernatants according to the manufacturer's
instructions. Briefly, 96-well plates were coated with capture antibodies overnight for
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each cytokine tested. On the next day, the plates were washed and blocked with 5% nonfat milk dissolved in PBS-T buffer for 2 hours. After washing the plates, dilutions of cell
culture supernatants were added into each well and incubated for 2 hours. Detection
antibodies (biotin-labeled) were added after washing out the diluted samples, and the
plates were incubated for another 2 hours. Then the plates were washed and streptavidinlabeled HRP was added for incubation of 1 hour. The plates were washed and the HRP
substrate (TMB) was added and the reaction can be stopped by 1M H2SO4. The values of
OD450 were subsequently measured.

Mitochondrial ROS detection
Mitochondrial ROS levels were measured using MitoSOX (Invitrogen). Briefly, LPSprimed cells were treated with liposomes for 6 h, loaded with 4 µM of MitoSOX for 15
min and washed twice with sterile PBS. The mean fluorescence intensity was determined
using a FACSCantoflow cytometer (BD Bioscience), and the data were analyzed using
FlowJo software (Treestar).

Fluorometric measurement of [Ca2+]i
The [Ca2+]i was measured in single cells as previously described(Han et al.,
2006). Briefly, cells were loaded for 30 min at 37°C with 2µM fura-2 AM in Tyrode
solution containing 138 mM NaCl, 2.7 mM KCl, 1.06 mM MgCl2, 1.8 mM CaCl2, 5.6
mM glucose and 12.4 mM HEPES (pH 7.4, adjusted with NaOH). The fluorescence
emission at 510 nm of fura-2 excited at 340 nm and 380 nm was acquired and analyzed
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offline with the NIS-Elements Advanced Research software package (Nikon) using an
inverted Nikon Ti-E microscope equipped with a Xenon lamp (Hammamatsu), a 40x 1.30
NA objective (Nikon) and an Evolve 512 EMCCD camera (Photomatrics). The EMCCD
camera was cooled to -80°C during imaging.

Quantitative real-time PCR analysis
RNA was isolated from murine bone marrow derived macrophages and was
reverse transcribed. Quantitative real-time PCR analysis was performed using the
StepOnePlus Real-time PCR system (Applied Biosystems). All gene expression data are
presented as the expression relative to HPRT1. The primer sequences are described in
Table 3.2.

Table 3.2 Primers sequences for real-time PCR analysis.
Mouse

Forward

Reverse

gene
Il1b

CTGCAGCTGGAGAGTGTGG

GGGGAACTCTGCAGACTCAA

Nlrp3

ATGGCTGTGTGGATCTTTGC

CACGTGTCATTCCACTCTGG

Hprt1

CTGGTGAAAAGGACCTCTCG TGAAGTACTCATTATAGTCAA
GGGCA
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In vivo mouse peritonitis model
Peritonitis was induced by the intraperitoneal injection of stimuli. Briefly, 6- to 8week-old mice were intraperitoneally injected with 1 mg MSU crystals, DOTAP
liposomes or 0.2 mg zymosan dissolved in 0.5 ml sterile PBS. Six hours after injection,
the mice were sacrificed by exposure to CO2 and the peritoneal cavities were washed
with 8 ml cold PBS. The recruited polymorphonuclear neutrophils present in the
peritoneal lavage fluid were quantified by flow cytometry using the neutrophil markers
Ly6G (BD Bioscience) and CD11b (eBioscience). The samples were acquired on a
FACSCantoflow cytometer (BD Biosciences) and the data were analyzed using FlowJo
software (Treestar).

Immunization
6- to 8-week-old mice deficient in TRPM2 or IL-1R and the corresponding wildtype controls were subcutaneously immunized with ovalbumin alone (40µg/mouse),
ovalbumin-encapsulated DOTAP liposomes or ovalbumin mixed with LPS, and the
animals were boosted once after two weeks. Ten days after the final immunization, the
mice were sacrificed by exposure to CO2 and the immune sera from the periphery blood
were isolated.
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Statistical analyses
All data are shown as mean ± s.d. or mean± s.e.m.. Statistical analysis was performed
using a two-tailed Student’s t-test for all studies. For all tests, P-values less than 0.05
were considered statistically significant.

CHAPTER 4
RESULTS
AIM1:

DETERMINE

WHETHER

LIPOSOMES

ACTIVATE

NLRP3

INFLAMMASOME TO INDUCE BIOACTIVE IL-1β FROM MACROPHAGES
Charged liposomes, but not neutral ones, induce mature IL-1β release from
macrophages
It is generally accepted that a “two-step” process is necessary for NLRP3
inflammasome-mediated IL-1β release. The first step requires NF-κB activation to induce
synthesis of pro-IL-1β, whereas the second step involves assembly of a large cytosolic
protein complex, termed inflammasomes, which lead to caspase-1 activation. Caspase-1
then cleaves pro-IL-1β into its mature form(Gross et al., 2011). To determine whether
liposomes can trigger activation of the NLRP3 inflammasome, we first tested whether
several liposomes, consisting of different phospholipids, can induce bioactive IL-1β
release in macrophages. Cationic (DOTAP, DC-Chol, and DDA) and anionic (DPPCDMPG) liposomes elicited IL-1β release from lipopolysaccharide (LPS)-primed murine
bone marrow-derived macrophages (BMDMs) and PMA-primed human THP-1 cells
(Figure 4.1), and the levels of secreted IL-1β were dependent on the dose and size of the
liposomes (Figure 4.2). Procaspase-1 was auto-cleaved after stimulation with charged
liposomes, and active caspase-1 was responsible for the maturation of IL-1β (Figure 4.3).
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Unlike IL-1β release, the secretion of both TNF and IL-6, which relies on NF-κB
activation, was not enhanced in LPS-primed BMDMs after liposomes stimulation
(Figure 4.4a, b). Consistently, liposomes alone did not induce either TNF or IL-6
secretion in unprimed macrophages (Figure 4.4c). In sharp contrast to the charged
liposomes, neutral liposomes, such as DOPC and PC-Chol liposomes, failed to trigger IL1β secretion (Figure 4.1 and Figure 4.5a, b). However, the incorporation of cationic
lipids into neutral liposomes rescued IL-1β secretion (Figure 4.5c), which suggests that
the charge of liposomes determines their ability to induce IL-1β release. Furthermore,
although liposomes induced low levels of cytotoxicity in macrophages (Figure 4.6), ATP
and uric acid, two known NLRP3 inflammasome agonists that are released from dying
cells(Mariathasan et al., 2006; Martinon et al., 2006), were not intermediates responsible
for liposome-induced IL-1β secretion (Figure 4.7).

Figure 4.1: Charged liposomes, but not neutral ones, induce IL-1β secretion from
macrophages. ELISA for IL-1β from the supernatants of (a) LPS-primed wild-type
BMDMs or (b) PMA-primed THP1 cells that were stimulated with either the indicated
liposomes (30 µg/ml for BMDMs and 50 µg/ml for THP1 cells) or alum (250 µg/ml for
BMDMs and 500 µg/ml for THP1 cells). Data are shown as mean ± s.d., and all data are
representative of at least three independent experiments.
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Figure 4.2: Charged liposomes induce IL-1β secretion in a dose and size dependent
manner. ELISA for IL-1β from supernatants of PMA-primed THP1 cells that were
stimulated with DOTAP liposomes of different doses (a) or sizes (b, 100 nm, 200 nm,
400 nm or 800 nm in diameter, respectively) for 16 h. Data are shown as mean ± s.d., and
are representative of three independent experiments.
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Figure 4.3: Charged liposomes activate caspase-1 to induce bioactive IL-1β release.
(a) Immunoblots of procaspase-1, activated caspase-1 (p10), pro-IL-1β and cleaved IL-1β
(p17) in the culture supernatants (Sup) and cell lysates (Lys) from LPS-primed BMDMs
after stimulation with indicated liposomes or alum. (b) IL-1β from supernatants of LPSprimed BMDMs that were pretreated with caspase-1 inhibitor (z-YVAD-fmk, 10 µM) for
45 min followed by stimulations with indicated liposomes or alum. Data are shown as
mean ± s.d. in b, and all data are representative of three independent experiments.
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Figure 4.4: Charged liposomes alone do not induce secretions of TNF and IL-6.
ELISA for TNF (a) or IL-6 (b) from supernatants of LPS-primed wild-type mouse
BMDMs that were stimulated with indicated liposomes. (c) TNF and IL-6 from
supernatants of wild-type unprimed BMDMs treated with LPS (100 ng/ml) or indicated
liposomes alone (30 µg/ml). Data are shown as mean ± s.d., and are representative of
three independent experiments.
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Figure 4.5: Neutral liposomes fail to induce IL-1β secretion in macrophages. ELISA
for IL-1β from supernatants of LPS-primed wild-type BMDMs (a) or PMA-primed THP1
cells (b) that were stimulated with indicated neutral liposomes for 24 h. (c) ELISA for IL1β from supernatants of PMA-primed THP1 cells that were stimulated with pure DOPC
or DOTAP liposomes, or chimeric liposomes (50 µg/ml) made with various molar ratio
of DOPC versus DOTAP. Data are shown as mean ± s.d., and are representative of at
least three independent experiments.
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Figure 4.6: Macrophage viabilities after treatment with charged liposomes or alum.
The levels of released Lactate dehydrogenase (LDH) were measured from the
supernatants of LPS-primed immortalized wild-type, Nlrp3−/− and Caspase 1−/−
macrophages that were stimulated with the DOTAP or DPPC-DMPG liposomes (70
µg/ml) or alum (500 µg/ml) for 6 h. Measurements were determined in triplicate and are
shown as mean ± s.d., and data are from one of three independent experiments.

The intact NLRP3 inflammasome machinery is required for liposome-induced IL-1β
secretion
Next, we sought to determine whether the intact NLRP3 inflammasome
machinery was essential for liposome-induced IL-1β secretion. First, we observed that
liposome-induced IL-1β secretion required LPS priming (Figure 4.7). Moreover,
macrophages deficient in NLRP3, ASC or caspase-1, three key components of the
NLRP3 inflammasome, all failed to respond to liposome stimulation after LPS priming
(Figure 4.8). In contrast, macrophages deficient in NLRC4, another Nod-like receptor
that recognizes bacterial flagellin(Miao et al., 2006), or AIM2 (absence in melanoma 2),
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an immune sensor for DNA(Fernandes-Alnemri et al., 2009; Hornung et al., 2009),
responded to charged liposomes stimulation in a manner similar to wild-type cells
(Figure 4.8 and Figure 4.9). These data collectively suggest that charged liposomes
induced IL-1β secretion specifically via activation of the NLRP3 inflammasome.
To further confirm that charged liposomes activate the NLRP3 inflammasome, we
next tested whether potassium efflux, a seemingly obligatory event during NLRP3
inflammasome activation(Gross et al., 2011; Jin and Flavell, 2010; Ogura et al., 2006),
was necessary for liposome-induced inflammasome activation. Indeed, the blockade of
potassium efflux with a high concentration of KCl drastically decreased the liposomeinduced NLRP3 inflammasome activation (Figure 4.10). Similar results were also
obtained when glibenclamide, an inhibitor that blocks potassium channels(Dostert et al.,
2009), was used (data not shown). Hereafter, we used DOTAP and DPPC-DMPG
liposomes as the representative cationic and anionic liposomes, respectively, to
investigate the mechanism by which charged liposomes activate the NLRP3
inflammasome.
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Figure 4.7: Liposomes-induced IL-1β release requires LPS priming. ELISA for IL-1β
from the supernatants of LPS-primed or unprimed wild-type BMDMs that were
stimulated with indicated liposomes (30 µg/ml) or alum (250 µg/ml). Data are shown as
mean ± s.d., and are representative of three independent experiments.

Figure 4.8: The NLRP3 inflammasome mediates liposomes-induced IL-1β release.
The IL-1β levels from the supernatants of LPS-primed immortalized mouse macrophages
from wild-type, Nlrp3−/−, Asc−/−, Caspase-1−/− or Nlrc4−/− mice that were stimulated with
liposomes (70 µg/ml). Data are shown as mean ± s.d., and are representative of three
independent experiments.
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Figure 4.9: Charged liposomes activate the NLRP3, but not AIM2, inflammasome.
(a-c) ELISA for IL-1β from supernatants of LPS-primed immortalized murine
macrophages from wild-type, Nlrp3−/−, Asc−/−, Caspase 1−/− or Aim2−/− mice that were
stimulated with indicated amount of empty cationic liposomes (Lipofectamine 2000) or
poly(dA:dT)-loaded liposomes for 6 h. Data are shown as mean ± s.d., and are
representative of three independent experiments.
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Figure 4.10: Potassium efflux is required for liposome-induced IL-1β secretion. (a-c)
ELISA for IL-1β from the supernatants of LPS-primed wild-type BMDMs that were
cultured in 150 mM of KCl or NaCl followed by stimulation with liposomes or alum.
Data are shown as mean ± s.d., and are representative of three independent experiments.

IL-1R signaling is critical for the adjuvant effect of liposomes
The mature bioactive IL-1β is a powerful proinflammatory cytokine that is
critically involved in both innate and adaptive immunities. It functions by signaling
through its receptor, IL-1R. Since it has been previously suggested that IL-1β-IL-1R
signaling axis is crucial for directing Th2 responses(Shaw et al., 2011), we next tested
whether the blockade of IL-1β-IL-1R signaling pathway would affect the humoral
immune response induced by antigen-encapsulated liposomes. As shown in Figure
4.11a, mice deficient in IL-1R had significantly reduced OVA-specific IgG1, the major
subtype of antibodies, in comparison with their wild-type littermates. Notably, deficiency
in IL-1R did not appear to affect the levels of OVA-specific IgGs when LPS was used as
the adjuvant (Figure 4.11b). This suggests that IL-1R deficiency does not yield a
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universal defect of mounting antibody responses. Together, these data indicate that IL1β-IL-1R signaling pathway is crucial for the adjuvanticity of liposomes.

Figure 4.11: IL-1R signaling is crucial for liposomes’ adjuvant effect. (a, b) Six- to
eight-week old female wild-type (Il1rl+/+) or Il1rl−/− mice were subcutaneously
immunized on day 0 and day 14 with 40 µg/mouse ovalbumin (OVA) alone or the same
amount of OVA encapsulated within DOTAP liposomes (a) or mixed with LPS (25
µg/mouse, b). On day 24, the mice were sacrificed, and sera were collected and analyzed
for OVA-specific IgG1, IgG2b, and IgG2c levels by ELISA. The data are shown as
geometrical mean ± s.e.m., and are representative of at least two independent experiments
(n=4-5 mice per group). *, p<0.05 versus controls. Statistical significance was
determined by the standard two-tailed Student’s t-test.
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AIM2:

DELINEATE

THE

MOLECULAR

MECHANISM

BY

WHICH

LIPOSOMES ACTIVATE THE NLRP3 INFLAMMASOME
Activation of the NLRP3 inflammasome requires cellular uptake of liposomes via
the actin-dependent endocytic pathway
NLRP3 is a cytosolic innate immune receptor which, upon activation, recruits
ASC and procaspase-1 to assemble into the inflammasome(Ogura et al., 2006).
Therefore, we next tested whether cellular uptake of liposomes was necessary for
activation of the NLRP3 inflammasome. The inhibition of the endocytic pathway with
cytochalasin D, a potent inhibitor of actin polymerization(Hornung et al., 2008), greatly
reduced liposome-induced IL-1β secretion, whereas ATP-induced NLRP3 inflammasome
activation, which does not require endocytic routes to activate the NLRP3
inflammasome(Hornung et al., 2008; Mariathasan et al., 2006), was largely unaffected
(Figure 4.12). These data suggest that the cellular internalization of liposomes is an
essential step for liposome-induced NLRP3 inflammasome activation.
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Figure 4.12: Activation of the NLRP3 inflammasome requires cellular uptake of
liposomes. IL-1β from the supernatants of PMA-primed THP1 cells that were pretreated
with cytochalasin D before stimulation with indicated liposomes (DOTAP liposome 40
µg/ml, DPPC-DMPG liposomes 100 µg/ml), alum (500 µg/ml) or ATP (2 mM). Data are
shown as mean ± s.d., and are representative of three independent experiments.

Lysosomal acidification and cathepsin B activity are dispensable for liposomeinduced NLRP3 inflammasome activation
We also sought to determine whether the lysosome-cathepsin B pathway was
involved in liposome-induced NLRP3 inflammasome activation. First, we found that the
pharmacologic inhibition of lysosomal acidification, a process critical for crystal-induced
inflammasome activation(Hornung et al., 2008), did not significantly affect liposomeinduced NLRP3 inflammasome-mediated IL-1β secretion (Figure 4.13a). Furthermore,
we also observed that lysosomal cathepsin B was not necessary for liposome-triggered
NLRP3 inflammasome activation because cathepsin B-deficient macrophages had only a
minimal reduction in the amount of secreted IL-1β after liposome stimulation (Figure
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4.13b). Notably, we observed that liposome-induced IL-1β secretion was decreased in
BMDMs that were pretreated with a cathepsin B inhibitor, CA-074-Me (Figure 4.13c).
These seemingly conflicting data may be due to the potential off-target side effects of
CA-074-Me(Dostert et al., 2009; Hornung et al., 2008; Newman et al., 2009). Taken
together, these data indicate that liposomes may either activate the NLRP3
inflammasome in a lysosome-independent manner or that several lysosomal cathepsins,
such as cathepsins B and L, are functionally redundant in mediating liposome-induced
NLRP3 inflammasome activation.
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Figure 4.13: Lysosomal cathepsin-B is dispensable for liposome-induced NLRP3
inflammasome activation. (a, c) ELISA for IL-1β from supernatants of LPS-primed
wild-type BMDMs that were pretreated with bafilomycin A1 (50 nM and 250 nM in a) or
CA-074-Me (10 µM in c) followed by stimulations with DOTAP or DPPC-DMPG
liposomes (30 µg/ml) or silica (500 µg/ml). (b) ELISA for IL-1β from supernatants of
LPS-primed immortalized murine wild-type or cathepsin B deficient (CatB−/−)
macrophages that were stimulated with DOTAP or DPPC-DMPG liposomes (70µg/ml).
Data are shown as mean ± s.d., and all data are representative of at least three
independent experiments. *, p<0.05, and **, p<0.01 versus controls. Statistical
significance was determined by the standard two-tailed Student’s t-test.
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Charged liposomes, but not neutral ones, trigger the production of ROS production
from mitochondria to direct NLRP3 inflammasome activation
Although mitochondrial ROS are essential for activation of the NLRP3
inflammasome(Kepp et al., 2011; Nakahira et al., 2011; Tschopp, 2011; Zhou et al.,
2011), a recent study also suggested a role for ROS during the first priming step of proIL-1β synthesis(Bauernfeind et al., 2011). Therefore, to specifically investigate the role
of ROS during activation of the NLRP3 inflammasome activation but not during pro-IL1β synthesis, we added ROS inhibitors after the synthesis of pro-IL-1β was completed.
This was achieved through prolonged LPS stimulation to saturate NF-κB activation
before ROS inhibition. As shown in Figure 4.14, prolonged LPS priming for 18 h
maximized the level of NF-κB mediated transcription, which was measured by the
production of NF-κB-dependent TNF.

Figure 4.14: Prolonged LPS stimulation saturates LPS-induced NF-κB activation.
ELISA for TNF from the supernatants of wild-type BMDMs that were stimulated with
100 ng/ml LPS for various periods of time as indicated. Data are shown as mean ± s.d.,
and are representative of at least three independent experiments.
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We then evaluated whether different liposomes could induce mitochondrial ROS
production. Notably, only the charged liposomes, but not neutral liposomes, induced the
robust generation of mitochondrial ROS in LPS-primed macrophages (Figure 4.15).
Moreover, even in the absence of an LPS priming step, charged liposomes remained
capable of increasing the mitochondrial ROS levels, suggesting that LPS pre-stimulation
is not necessary for mitochondrial ROS induction (data not shown). Next, we used the
pharmacological inhibitor diphenyleneiodonium (DPI), which blocks mitochondrial ROS
production when used at high concentrations(Bulua et al., 2011; Holland and Sherratt,
1972), to further investigate whether mitochondrial ROS were involved in liposomeinduced NLRP3 inflammsome activation. The addition of DPI prior to liposome
stimulation drastically reduced liposome-induced mitochondrial ROS production and IL1β release (Figure 4.16). Notably, the reduction in IL-1β secretion was not due to the
inhibition of NF-κB activation by DPI because neither the levels of pro-IL-1β or Nlrp3
were significantly changed after the 18 h LPS priming step (Figure 4.17). In contrast to
DPI, pretreatment of the macrophage with VAS2870, which blocks NADPH oxidase
(NOX)-generated ROS(Stielow et al., 2006), did not affect liposome-induced IL-1β
secretion, suggesting that mitochondria, rather than NOX-derived ROS drive the NLRP3
inflammasome activation (Figure 4.18). Moreover, because activation of the AIM2
inflammasome by poly(dA:dT) was not affected by DPI treatment (Figure 4.16b), the
inhibition of mitochondrial ROS seemed to specifically affect the NLRP3 inflammasome.
Similar results were also observed when other ROS inhibitors, such as (2R, 4R)-4aminopyrrolidine-2,4-dicarboxylate (APDC) or N-acetyl-cysteine (NAC), were used
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(data not shown). Taken together, these data indicate that mitochondrial ROS production
is essential for NLRP3 inflammasome activation by charged liposomes and that the
failure of neutral liposomes to activate the NLRP3 inflammasome directly correlates with
their inability to induce mitochondrial ROS.

Figure 4.15: Charged but not neutral liposomes induce mitochondrial ROS
production. Mitochondrial ROS production was measured by flow cytometry in LPSprimed BMDMs that were stimulated with indicated liposomes (30 µg/ml) and labeled
with MitoSOX. Data are shown as mean ± s.d., and are representative of at least three
independent experiments.
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Figure 4.16: Inhibition of mitochondrial ROS abolishes liposome-induced
inflammasome activation. (a) LPS-primed wild-type BMDMs were pretreated with DPI
for 30 min and then stimulated with indicated liposomes (30 µg/ml) for 6 h. The cells
were then stained with MitoSOX and the levels of mitochondrial ROS were normalized
to the untreated controls (n=3). (b) ELISA for IL-1β from the supernatants of LPSprimed (18 h) BMDMs that were pretreated with DPI before stimulation with indicated
liposomes (30 µg/ml) or poly(dA:dT) (2 µg/ml). Data are shown as mean ± s.d., and the
data are representative of three (a) and four (b) independent experiments.

Figure 4.17: DPI treatment does not affect Il1b and Nlrp3 mRNAs after prolonged
LPS priming. The mRNA levels of Il1b (left) and Nlrp3 (right) were quantified by realtime RT-PCR in wild-type BMDMs that were stimulated as indicated. DPI (25 µM) was
added after 18 h LPS priming but 45min before addition of liposomes. Gene expression
data are presented as relative expression to HPRT1, and the gene relative expression level
in 24 h LPS treated wild-type macrophages (DMSO group) were designated as 1. Data
are representative of three independent experiments.
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Figure 4.18: Inhibition of NADPH oxidase does not affect liposome-induced IL-1β
secretion. The levels of IL-1β were measured by ELISA from supernatants of LPSprimed wild-type BMDMs that were pretreated with VAS2870 for 30 min followed by
stimulations with DOTAP or DPPC-DMPG liposomes (30 µg/ml) for 6 h. Data are
shown as mean ± s.d., and are representative of three independent experiments.

AIM3: DELINEATE WHETHER TRPM2 IS CRITICAL FOR ACTIVATION OF
THE

NLRP3

INFLAMMASOME

IN

RESPONSE

TO

PARTICLES

STIMULATION
Particulates (e.g. liposomes and crystals) induce a ROS-dependent Ca2+ influx via
the TRPM2 channel
Our findings indicated that, similar to crystals(Tschopp and Schroder, 2010),
liposomes activate the NLRP3 inflammasome via the induction of mitochondrial ROS.
However, little is known about the mechanism by which ROS promote NLRP3
inflammasome activation. Due to the existence of a diverse pool of stimuli(Gross et al.,
2011), these agonists may activate a common signaling intermediate that directs assembly
of the NLRP3 inflammasome. Recently, it has been shown that accumulation of ROS can
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induce a calcium influx via the TRPM2 (transient receptor potential melastatin 2)
channel(Hecquet and Malik, 2009; Yamamoto et al., 2008). TRPM2 is expressed by
immune cells, such as dendritic cells, monocytes, macrophages, PMNs and lymphocytes,
and is a calcium-permeable nonselective cation channel that plays a crucial role in innate
immune regulation(Sumoza-Toledo and Penner, 2011). TRPM2-mediated calcium influx
has been implicated in ROS-induced chemokine production in monocytes(Yamamoto et
al., 2008). Notably, TRPM2-deficient mice are also susceptible to infection of Listeria
monocytogenes(Knowles

et

al.,

2011),

a

known

activator

of

the

NLRP3

inflammasome(Kim et al., 2010; Mariathasan et al., 2006). Because calcium appears to
be a key mediator of various signaling events under stressed conditions, we hypothesize
that liposomes/crystals induce ROS-dependent TRPM2-medidated calcium influx, which
eventually signals assembly and activation of the NLRP3 inflammasome.
As shown in Figure 4.19, we first observed that charged liposomes or crystals
induced the increase in the concentration of intracellular free calcium ([Ca2+]i). This
elevation in [Ca2+]i was due to calcium influx across the plasma membrane because the
removal of extracellular calcium from the buffer solution dramatically inhibited the
increase of [Ca2+]i (Figure 4.20 and Figure 4.21). Furthermore, blockade of
mitochondrial ROS by DPI also prevented liposome/crystal-induced calcium influx,
suggesting that calcium influx is ROS-dependent. Notably, BMDMs deficient in TRPM2
had similar defects in calcium influx after liposome/crystal stimulation, indicating that
calcium influx is mediated by the TRPM2 channel (Figure 4.20 and Figure 4.21). To
further verify the role of TRPM2 in mediating calcium influx, we tested whether
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inhibition of TRPM2 activation affected liposome/crystal-induced calcium influx.
TRPM2 channel can be gated by ADP-ribose, a metabolic product formed during cellular
exposure to ROS(Knowles et al., 2011; Sumoza-Toledo and Penner, 2011). Therefore, we
treated LPS-primed wild-type BMDMs with DPQ, an inhibitor of poly(ADP-ribose)
polymerase, to prevent ADP-ribose accumulation(Fonfria et al., 2004; Suto et al., 1991)
before the addition of liposomes/crystals to determine whether the calcium influx was
affected. As expected, DPQ significantly reduced calcium influx in response to
stimulation with particles (Figure 4.20 and Figure 4.21). These data collectively indicate
that stimulation of macrophages with either liposomes or crystals can trigger ROSdependent TRPM2-mediated calcium influx.
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Figure 4.19: Charged liposomes and crystals induce cytosolic calcium elevation. (a)
The change in [Ca2+]i over time was represented by the fluorescence of Fura-2 at 340 nm
to that at 380 nm (F340/F380) and (b) the maximum [Ca2+]i elevations, represented by
ΔF340/F380, are shown in LPS-primed wild-type BMDMs treated with medium alone,
cationic liposomes (DOTAP, 30 µg/ml), neutral liposomes (DOPC, 30 µg/ml), anionic
liposomes (DPPC-DMPG, 30 µg/ml) or silica crystals (300 µg/ml). The data are
representative of at least three independent experiments and are shown as mean ± s.e.m.
in b (n=22-31).
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Figure 4.20: Charged liposomes and crystals induce a ROS-dependent TRPM2mediated calcium influx. (a) The time-dependent change in [Ca2+]i, represented by
F340/F380, in the LPS-primed Trpm2+/+ BMDMs cultured in calcium-containing solution
that were pretreated with DPI (25 µM) or DPQ (200 µM) for 45min before the addition
of the indicated liposomes (30 µg/ml) or crystals (alum, 400 µg/ml; silica, 300 µg/ml) is
shown. The same doses of liposomes or crystals were also used to stimulate the LPSprimed Trpm2−/− BMDMs cultured in calcium-containing solution. The [Ca2+]i change
over time, represented by F340/F380, after stimulation with liposomes or crystals in LPSprimed Trpm2+/+ BMDMs cultured in calcium-free 0.5 mM EGTA-containing solution is
also shown. Inflammasome agonists were added 1 min after the initiation of calcium
recording as shown in a. (b) The maximum [Ca2+]i elevations, represented by
ΔF340/F380, are shown for LPS-primed BMDMs in response to the stimulations
described in a. The data are representative of at least three independent experiments and
are shown as mean ± s.e.m. in b (n=21-34).
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Figure 4.21: MSU crystals induce a TRPM2-mediated Ca2+ influx in macrophages.
(a) Time-dependent change of [Ca2+]i, represented by F340/F380, was shown in LPSprimed Trpm2+/+ BMDMs cultured in calcium-containing solution that were pretreated
with DPI (25 µM) or DPQ (200 µM) for 45min for before the addition of MSU crystals
(250 µg/ml). The same doses of MSU crystals were used to stimulate the LPS-primed
Trpm2−/− BMDMs cultured in calcium-containing solution. The [Ca2+]i over time after
additions of these stimuli into LPS-primed Trpm2+/+ BMDMs cultured in calcium-free
0.5 mM EGTA-containing solution are also shown. MSU crystals were added 1 min after
the starting of calcium recording. (b) The maximum [Ca2+]i elevations, represented by
ΔF340/F380, were shown in LPS-primed BMDMs in response to the stimulations
described in a. Data are representative of two independent experiments and are shown as
mean ± s.e.m. in b (n=21-38).
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TRPM2-mediated Ca2+ influx regulates particle-induced IL-1β secretion
We next determined whether TRPM2-mediated calcium influx was critical for IL1β release. Trpm2−/− BMDMs demonstrated significantly reduced IL-1β secretion in
responses to stimulation with the liposomes DOTAP and DPPC-DMPG or the crystals of
alum, silica and MSU. In contrast, poly(dA:dT)-induced IL-1β secretion, which is AIM2
inflammasome-dependent(Fernandes-Alnemri et al., 2009; Hornung et al., 2009), was
largely unaffected (Figure 4.22). Similarly, the removal of extracellular calcium from the
culture medium significantly impaired the particulate agonist-, but not poly(dA:dT)-,
induced IL-1β release (Figure 4.22).

Figure 4.22: TRPM2-mediated Ca2+ influx regulates IL-1β secretion. ELISA for IL1β from the supernatants of LPS-primed wild-type (Trpm2+/+) or Trpm2−/− BMDMs that
were stimulated with indicated liposomes (30 µg/ml), crystals (alum, 250 µg/ml; silica
and MSU crystals, 200 µg/ml) or poly(dA:dT) (2 µg/ml) for 6 h in calcium-containing or
calcium-free medium. All data are representative of at least three independent
experiments, and are shown as mean ± s.d.. *, p < 0.05, and **, p<0.01 versus controls.
Statistical significance was determined by the standard two-tailed Student’s t-test.
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Furthermore, we observed that the decrease in the mature IL-1β secretion in
Trpm2−/− BMDMs was not due to the reduction in either pro-IL-1β or NLRP3 levels, the
genes for which are regulated by NF-κB(Bauernfeind et al., 2009; Gross et al., 2011)
because TRPM2 deficiency affected neither pro-IL-1β nor NLRP3 (Figure 4.23 and data
not shown). Consistent with this finding, TNF secretion was not affected by TRPM2
deficiency (Figure 4.24). Moreover, the inhibition of TRPM2 activation by DPQ also
significantly impaired liposome-/crystal-, but not poly(dA:dT)-, induced IL-1β secretion
(Figure 4.25). In contrast to the wild-type cells, Trpm2−/− BMDMs did not display any
further reduction in IL-1β secretion after DPQ treatment (Figure 4.26), indicating that
DPQ treatment specifically blocked TRPM2-mediated IL-1β release. It has been shown
that the inhibition of key enzymes in the mitochondrial respiratory chain can artificially
increase the levels of mitochondrial ROS and trigger spontaneous NLRP3 inflammasome
activation in the absence of inflammasome stimuli(Zhou et al., 2011), therefore we next
verified the role of TRPM2 in mediating IL-1β release under these conditions. To do so,
we artificially induced the accumulation of mitochondrial ROS with antimycin A, an
inhibitor that specifically blocks the respiratory chain complex III, and determined
whether TRPM2 deficiency affected antimycin A-induced IL-1β release. Indeed, we
found that Trpm2−/− BMDMs had significantly reduced secretion of IL-1β, but not TNF
(Figure 4.27). Consistently, TRPM2 deficiency also decreased IL-1β secretion in
response to direct stimulation with ROS, such as H2O2 (Figure 4.27). Together, these
results suggest a critical role for TRPM2-mediated calcium influx in bioactive IL-1β

63
release, and demonstrate that TRPM2 deficiency specifically impairs the processing of
immature pro-IL-1β into its mature form.
It should be noted that in addition to TRPM2-dependent IL-1β release,
liposomes/crystals also induced TRPM2-independent IL-1β secretion. This effect was
most likely mediated by ER-calcium release via IP3R, as suggested in a recent study by
Murakami et al.(Murakami et al., 2012). In support of the hypothesis that calcium influx
and ER calcium release are both essential for NLRP3 inflammasome activation, we
observed that the intracellular calcium chelator BAPTA-AM, which blocks [Ca2+]i
elevation regardless of the source of calcium, almost completely inhibited IL-1β release
(Figure 4.28) whereas the inhibition of either calcium influx or intracellular ER calcium
release(Murakami et al., 2012) only partially reduced IL-1β secretion. Together, these
results demonstrate that both calcium influx and ER calcium release are critical for
activation of the NLRP3 inflammasome.
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Figure 4.23: TRPM2 deficiency does not affect the levels of pro-IL-1β. (a) The levels
of pro-IL-1β mRNA were quantified by real-time RT-PCR in LPS-primed Trpm2+/+ or
Trpm2−/− BMDMs after stimulation with indicated liposomes and crystals. The gene
expression data are presented as expression relative to HPRT1, and the relative gene
expression levels in wild-type macrophages were designated as 1. (b) Immunoblots for
pro-IL-1β and β-actin in the cell lysates from LPS-primed Trpm2+/+ or Trpm2−/− BMDMs
after stimulation with liposomes or crystals. All data are representative of at least three
independent experiments, and are shown as mean ± s.d. in a.
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Figure 4.24: TRPM2 deficiency does not affect TNF secretion. ELISA TNF from the
supernatants of LPS-primed wild-type (Trpm2+/+) or Trpm2−/− BMDMs that were
stimulated with indicated liposomes (30 µg/ml) or crystals (alum, 250 µg/ml; silica and
MSU crystals, 200 µg/ml) for 6 h in calcium-containing medium. All data are
representative of at least three independent experiments, and are shown as mean ± s.d..

Figure 4.25: Inhibition of TRPM2 by DPQ significantly impairs liposome-induced
IL-1β secretion. IL-1β from the supernatants of LPS-primed wild-type BMDMs that
were pretreated with DPQ (200 µM) followed by inflammasome agonist stimulation All
data are representative of at least three independent experiments, and are shown as mean
± s.d..
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Figure 4.26: DPQ does not further reduce particles-induced IL-1β release in
Trpm2−/− BMDMs. ELISA for IL-1β from supernatants of LPS-primed Trpm2−/−
BMDMs that were pretreated with DPQ (200 µM) followed by stimulations with
indicated liposomes or crystals. Data are shown as mean ± s.d., and are representative of
three independent experiments.

Figure 4.27: TRPM2 deficiency impairs ROS-induced IL-1β secretion . IL-1β (left)
or TNF (right) from the supernatants of LPS-primed wild-type BMDMs that were
stimulated with antimycin A (20 µg/ml) or H2O2 (10 mM) for 6 h. All data are
representative of at least three independent experiments, and are shown as mean ± s.d.. *,
p < 0.05, and **, p<0.01 versus controls. Statistical significance was determined by the
standard two-tailed Student’s t-test.
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Figure 4.28: Blocking [Ca2+]i elevation abolishes the NLRP3 inflammasome
activation by particulates. ELISA for IL-1β (a) or TNF (b) from supernatants of LPSprimed wild-type BMDMs that were pretreated with BAPTA-AM (25 µM) followed by
stimulations with liposomes or crystals. Data are shown as mean ± s.d., and are
representative of three independent experiments.

TRPM2 is critical for particle-induced, NLRP3-mediated caspase-1 activation
To determine the mechanism by which TRPM2 deficiency leads to impaired
processing of bioactive IL-1β, we tested whether Trpm2−/− BMDMs were defective in
caspase-1 activation. As shown in Figure 4.29, deficiency in TRPM2 or the blockade of
[Ca2+]i increase via BAPTA-AM drastically reduced the level of mature caspase-1 in
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response to liposomes or crystals. This defect was not due to impaired mitochondrial
ROS production because neither genetic ablation of TRPM2 nor removal of extracellular
calcium impaired mitochondrial ROS production after liposome stimulation (Figure 4.30
and Figure 4.31). Moreover, we found that Nlrp3−/− macrophages displayed a
comparable level of calcium influx as wild-type cells in response to liposome stimulation
(Figure 4.32), suggesting that TRPM2-mediated calcium influx is an early event before
assembly of the NLRP3 inflammasome. Together, these data indicate that ROSdependent calcium influx via the TRPM2 channel is critical for NLRP3 inflammasomemediated caspase-1 activation.

Figure 4.29: Blocking [Ca2+]i elevation or inhibiting TRPM2 impairs caspase-1
activation by particulates. (a) Immunoblots of procaspase-1 in lysates and caspase-1
p10 in culture supernatants of LPS-primed Trpm2+/+ and Trpm2−/− BMDMs that were
stimulated with indicated liposomes (30 µg/ml) or crystals (250 µg/ml). (b) Immunoblots
of procaspase-1 and caspase-1 p10 in LPS-primed wild-type BMDMs that were preteated
with either BAPTA-AM (25 µM) or DMSO before stimulation with the indicated
liposomes (50 µg/ml) and crystals (400 µg/ml). One of three independent experiments is
shown in a and b.
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Figure 4.30: TRPM2 deficiency does not affect liposome-induced mitochondrial
ROS production. (a-c) LPS-primed Trpm2+/+ or Trpm2−/− BMDMs were treated with
indicated liposomes (30 µg/ml) for 6 h. The cells were then stained with MitoSOX and
the levels of mitochondrial ROS were measured by flow cytometry (a, b). The data are
representative for three experiments and are normalized to the untreated controls (c, n=3).
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Figure 4.31: Removal of extracellular calcium does not impair mitochondrial ROS
production. LPS-primed wild-type BMDMs were treated with indicated liposomes (30
µg/ml) for 6 h in the presence of calcium containing or calcium free medium. Then the
cells were stained with MitoSOX and the levels mitochondrial ROS were measured by
flow cytometry. Data are representative for two independent experiments and are
normalized to untreated controls (n=3).

Figure 4.32: Calcium influx is an early event before the assembly of NLRP3
inflammasome. The maximum [Ca2+]i elevations, represented by ΔF340/F380, are
shown for LPS-primed immortalized murine wild-type or Nlrp3−/− macrophages in
response to stimulation with liposomes (70 µg/ml). The data are shown as mean ± s.e.m.
(n=23-28), and are representative of two independent experiments.

Along with the role of calcium influx in activation of the NLRP3 inflammasome,
potassium efflux has been shown to be essential for inflammasome activation by most, if
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not all, NLRP3 inflammasome agonists(Jin and Flavell, 2010; Tschopp and Schroder,
2010). It appears that the mobilization of both cations across the plasma membrane is
crucial for NLRP3 inflammasome activation. Consistent with a recent study(Gross et al.,
2012), we found that the blockade of potassium efflux did not prevent calcium influx
induced by NLRP3 inflammasome agonists (Figure 4.33), which further verifies that in
addition to potassium efflux, calcium influx is also a crucial event for NLRP3
inflammasome activation. Because TRPM2 is a non-selective cation channel that allows
the passage of both calcium and potassium(Sumoza-Toledo and Penner, 2011), it is
possible that TRPM2 deficiency may also affect potassium efflux. However, as the
removal of extracellular calcium did not further decrease the particulate-induced NLRP3
inflammasome activation in Trpm2−/− BMDMs (Figure 4.22), the defect of NLRP3
inflammasome activation in TRPM2-deficient cells is most likely due to impaired
calcium influx.
It should be noted that ATP-induced NLRP3 inflammasome activation was also
primarily dependent on calcium influx (Figure 4.34). However, in contrast to particulate
agonists of the NLRP3 inflammasome, ATP uses P2X7, but not TRPM2, to induce
calcium influx and NLRP3 inflammasome activation (Figure 4.34). Consistent with this
notion, deficiency in P2X7 did not affect calcium influx triggered by particulate stimuli
(Figure 4.35). Taken together, these results suggest that calcium influx is a general
proximal step during NLRP3 inflammasome activation, and that different activators of
the NLRP3 inflammasome may use distinct plasma membrane ion channels to mediate
calcium influx.
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Figure 4.33: Blocking potassium efflux does not affect calcium influx. The maximum
[Ca2+]i elevations, represented by ΔF340/F380, are shown for LPS-primed immortalized
murine wild-type or Nlrp3−/− macrophages in response to stimulation with liposomes (70
µg/ml). The data are shown as mean ± s.e.m. (n=23-28), and are representative of two
independent experiments.
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Figure 4.34: ATP activates the NLRP3 inflammasome by inducing Ca2+ influx via
P2X7 channel. Time-dependent change of [Ca2+]i, represented by F340/F380, was shown
in LPS-primed Trpm2+/+ and Trpm2−/− BMDMs (a, left pannel) or P2X7+/+ and P2X7−/−
BMDMs (b, left pannel) cultured in Ca2+-containing solution that were stimulated with
ATP (2 mM). The calcium flux over time after ATP stimulation in LPS-primed Trpm2+/+
BMDMs cultured in calcium-free 0.5 mM EGTA-containing solution was also shown.
The maximum [Ca2+]i elevations (right panels of a and b), represented by ΔF340/F380,
were shown in in LPS-primed BMDMs in response to the ATP stimulation. ATP was
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added 1 min after the starting of calcium recording. Data are representative of four
independent experiments and are shown as mean ± s.e.m. in a (n=20-36) and b (n=2228). (c) ELISA for IL-1β from supernatants of LPS-primed P2X7−/− or wild-type (P2X7+/+)
BMDMs that were pretreated with BAPTA-AM (25 µM) followed by stimulations with
ATP. (d) IL-1β from supernatants of LPS-primed Trpm2+/+ or Trpm2−/− BMDMs that
were treated with ATP. (e) IL-1β from supernatants of LPS-primed wild-type BMDMs
that were stimulated with ATP in calcium-containing or calcium-free medium. Data are
shown as mean ± s.d. in c-e, and are representative of three independent experiments.

Figure 4.35: Deficiency in P2X7 does not affect liposome-induced [Ca2+]i elevation.
(a) Time-dependent change of [Ca2+]i, represented by F340/F380, was shown in LPSprimed P2X7+/+ and P2X7−/− BMDMs cultured in calcium-containing solution that were
stimulated with DOTAP liposomes (30 µg/ml). DOTAP liposomes were added 1 min
after the starting of calcium recording. (b) The maximum [Ca2+]i elevations, represented
by ΔF340/F380, were shown in LPS-primed BMDMs in response to the stimulation as
described in a. Data are representative of two independent experiments, and are shown as
mean ± s.e.m. in b (n=25-36).
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TRPM2 is crucial for NLRP3 inflammasome activation in vivo
To further validate the role of TRPM2 in mediating NLRP3 inflammasome
activation in vivo, we determined whether TRPM2 deficiency affected crystal-/liposomeinduced IL-1β secretion and subsequent neutrophil recruitment after intraperitoneal
injections of these particulate stimuli. We first observed that the level of IL-1β in the
peritoneal fluid of the Trpm2−/− mice was significantly reduced as compared to that from
wild-type mice after injection with either MSU crystals or DOTAP liposomes (Figure
4.36). Moreover, particle-induced neutrophil recruitment was also significantly decreased
in Trpm2−/− mice, which was similar to that observed in Il1rl−/− mice (Figure 4.37). In
contrast, neutrophil recruitment was not affected by either TRPM2 or IL-1R deficiency in
response to an intraperitoneal challenge with zymosan, a Toll-like receptor 2 agonist
(Figure 4.38). These data collectively indicate that TRPM2 is essential for NLRP3
inflammasome activation in vivo.
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Figure 4.36: TRPM2 is critical for particle-induced IL-1β release in vivo. The IL-1β
concentration (a, b) were quantified in peritoneal lavage fluid from wild-type (Trpm2+/+),
or Trpm2−/− mice 6 h after intraperitoneal injection of PBS supplemented with either
MSU crystals (a) or DOTAP liposomes (b). The data are representative of two
independent experiments (mean and s.e.m. of three to five mice per group). *, p<0.05
versus controls. Statistical significance was determined by the standard two-tailed
Student’s t-test.
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Figure 4.37: TRPM2 and IL-1R mediate particle-induced peritonitis. The neutrophil
recruitment (a-d) were quantified in peritoneal lavage fluid from wild-type (Il1rl+/+ and
Trpm2+/+), Il1rI−/− or Trpm2−/− mice 6 h after intraperitoneal injection of PBS
supplemented with either MSU crystals (a, c) or DOTAP liposomes (c, d). The data are
representative of two independent experiments (mean and s.e.m. of three to five mice per
group). *, p<0.05 versus controls. Statistical significance was determined by the standard
two-tailed Student’s t-test.
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Figure 4.38: Deficiency in TRPM2 or IL-1R does not affect zymosan-induced
peritonitis. IL-1β concentrations (a) and neutrophils influx (b) were quantified in
peritoneal lavage fluid from wild-type (Il1rl+/+ or Trpm2+/+), Il1rI−/− or Trpm2−/− mice 6h
after intraperitoneal injection of PBS (0.5 ml) supplemented with zymosan (0.2 mg). Data
are representative of two independent experiments (mean and s.e.m. of five mice per
group).

TRPM2 is crucial for the adjuvant effect of liposomes in vivo
Finally, we tested whether deficiency in TRPM2, which results in decreased IL1β secretion, would affect the adjuvanticity of liposomes in vivo. As shown in Figure
4.39, the level of ovalbumin (OVA)-specific IgG1 was significantly reduced in Trpm2−/−
mice after immunization with OVA-encapsulated DOTAP liposomes. However, in
contrast to the liposomal adjuvant, a deficiency in either TRPM2 did not impair the
optimal levels of anti-OVA antibodies when LPS, a Toll-like receptor 4 agonist, was used
as the adjuvant (Figure 4.39), which suggests that TRPM2- and IL-1R-deficient mice do
not have a general defect in mounting an antibody response. Taken together, these data
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indicate that TRPM2 and IL-1R are essential for the induction of an optimal antibody
response against the antigens that are encapsulated within liposomes.

Figure 4.38: TRPM2 is critical for liposome’s adjuvanticity. Six- to eight-week old
female wild-type (Trpm2+/+) or Trpm2−/− mice were subcutaneously immunized on day 0
and day 14 with 40 µg/mouse ovalbumin (OVA) alone or the same amount of OVA
encapsulated within DOTAP liposomes (a) or mixed with LPS (25 µg/mouse, b). On day
24, the mice were sacrificed, and sera were collected and analyzed for OVA-specific
IgG1, IgG2b, and IgG2c levels by ELISA. The data are shown as geometrical mean ±
s.e.m., and are representative of at least two independent experiments (n=4-5 mice per
group). *, p<0.05 versus controls. Statistical significance was determined by the standard
two-tailed Student’s t-test.

CHAPTER 5
DISCUSSION
Liposomes are promising immune adjuvants and delivery vectors for the
treatment of both infectious and cancerous diseases(Allison and Gregoriadis, 1974;
Christensen et al., 2007; Slingerland et al., 2012). Therefore, understanding the innate
immune recognition process for liposomes will not only mechanistically define/improve
their adjuvant effect but also help to prevent any undesirable inflammatory responses,
particularly when liposomes are used as drug-delivery vehicles for anti-cancer therapies.
In this thesis study, I identified the NLRP3 inflammasome as a novel innate immune
sensor for liposomes. Notably, only the charged, but not neutral, liposomes activated the
NLRP3 inflammasome, which is most likely due to the fundamental differences in their
induction of mitochondrial ROS. Because the plasma membrane potential is tightly
associated with the oxidative state in phagocytes(DeCoursey, 2010; DeCoursey et al.,
2003; Murphy and DeCoursey, 2006), it is plausible that charged, but not neutral,
liposomes could induce cellular oxidative stress via alteration of the plasma membrane
potential, which would eventually result in NLRP3 inflammasome activation. Therefore,
charged liposomes may be more suitable as immune adjuvants, whereas neutral
liposomes may be more suitable as delivery vectors for anti-cancer drugs.
We also performed additional experiments to test whether the extent of NLRP3
inflammasome activation depends upon the dose and size of the liposomes. As expected,
80
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charged liposomes induce IL-1β secretion in a dose dependent manner. Interestingly, the
size of liposome also determined the amount of IL-1β secretion. It seems that, within the
range of 100nm to 800nm in diameter, the liposome-induced IL-1β secretion displayed a
liner positive correlation with the size of liposomes.
To mechanistically understand how liposomes activate the NLRP3 inflammasome,
we first tested if potassium efflux, a seemingly obligatory event for NLRP3
inflammasome activation by essentially all its known activators, was required for
liposome-induced inflammasome activation. Indeed, similar to all other known activators,
the inhibition of potassium efflux completely abolished NLRP3 inflammasome activation
by liposomes. We next tested whether the uptake of liposomes is a necessary step for
NLRP3 inflammasome activation. Indeed, we found that the inhibition of phagocytosis in
macrophages drastically impaired liposome-induced NLRP3 inflammasome activation.
This is likely due to that the uptake of liposomes is required to induce a stress signal that
can be sensed by the intracellular innate immune receptor, NLRP3. Interestingly,
although the initial phagocytic pathway is required, we found that the lysosome-cathepsin
B pathway seems dispensable for liposome-induced NLRP3 inflammasome activation
because the inhibition of lysosome acidification or genetic blockade of cathepsin B
activity did not significantly affect liposome-induced NLRP3 inflammasome activation.
This suggests that the signals necessary for directing NLRP3 inflammasome activation by
liposomes appear to be independent of lysosome-derived contents.
ROS has been proposed to be a key player that drives NLRP3 inflammasome
activation by most activators. It has been demonstrated that artificially induction of ROS,
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in the absence of NLRP3 inflammasome agonists, can trigger spontaneous NLRP3
inflammasome activation and subsequent proinflammatory cytokine secretion. Moreover,
the blockade of ROS generation from mitochondria by pharmocologica or genetic means
can strongly inhibit NLRP3 inflammasome activation by a number of stimuli. It appears
that ROS plays a central role in orchestrating the immune responses by activating the
NLRP3 inflammasome.
Although an essential role for mitochondrial ROS has recently been implicated in
activation of the NLRP3 inflammasome(Kepp et al., 2011; Tschopp, 2011), the precise
mechanism underlying ROS-induced inflammasome activation remains elusive. In this
thesis study, I identified a novel signaling axis originating from ROS production,
followed by TRPM2-mediated calcium influx and ultimately activation of the NLRP3
inflammasome. Therefore, these findings provide at least one mechanistic link that
connects oxidative stress with NLRP3 inflammasome activation. Furthermore, the
identification of TRPM2 as the responsible channel for calcium influx during NLRP3
inflammasome activation also further advanced our understanding of how calcium
mobilization occurs upon stimulation with NLRP3 agonists.
Besides TRPM2, a previous study has also identified TXNIP (thioredoxininteracting protein) as another link between oxidative stress and NLRP3 inflammasome
activation. Upon stimulation with NLRP3 agonists, TXNIP disassociates with its binding
protein TRX (thioredoxin) which allows the direct binding of TXNIP to NLRP3.
However, TXNIP does not seem to be a universal regulator of NLRP3 inflammasome
because several recent studies have shown that TXNIP is dispensable for NLRP3

83
inflammasome activation by other stimuli. Nonetheless, further studies are indeed
necessary to delineate the possible relationship between TNXIP, TRPM2, and NLRP3
inflammasome activation. It would be interesting to see if genetic ablation of TXNIP may
affect TRPM2 mediated calcium influx. Alternatively, calcium mobilization might also
be a prerequisite for TXNIP to interact and activate NLRP3.
In addition to TRPM2-dependent IL-1β release, we observed that a portion of
particle-induced IL-1β secretion was independent of TRPM2-mediated calcium influx but
instead was dependent on calcium release from intracellular stores. This observation is
consistent with a recent report by Murakami et al. that demonstrated a role for IP3Rmediated
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inflammasome(Murakami et al., 2012). Additionally, two recent studies have also
demonstrated that extracellular calcium elevation, which is a common phenomenon under
local inflammation when cell’s integrity is compromised, can serve as a danger signal
which ultimately induces IP3R-mediated calcium release from ER to activate the NLRP3
inflammasome.
Although it is clear that both calcium influx and ER calcium release are critical
for IL-1β secretion, how multiple calcium mobilization events cooperatively trigger
NLRP3 inflammasome activation remains to be further defined. Recently, a report by
Zhou et al. demonstrated a close interaction between the ER and mitochondria in
response to NLRP3 inflammasome stimuli. Because calcium overload in mitochondria is
essential for ROS production, it is plausible that ER-mitochondria contact may be
beneficial for rapid calcium flow from the ER into mitochondria, which may facilitate the
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generation of sufficient mitochondrial ROS, particularly at later stage during activation of
the NLRP3 inflammasome. Moreover, Murakami et al. have also demonstrated that in
addition to facilitating mitochondrial ROS production, ER-derived calcium is also
essential for mitochondria to maintain a damaged state(Murakami et al., 2012).
Mitochondrial damage has been shown to induce the release of mitochondrial DNA
(mtDNA) into the cytosol, which also activates the inflammasomes(Nakahira et al., 2011;
Shimada et al., 2012). In addition to mtDNA, our study demonstrates that ROS released
from the damaged mitochondria activate the TRPM2 channel, which results in calcium
influx across the plasma membrane. Because blocking TRPM2-mediated calcium
mobilization drastically impaired caspase-1 activation and did not affect mitochondrial
ROS production, it is possible that, unlike ER-derived calcium, TRPM2-mediated
calcium influx may directly signal activation of the NLRP3 inflammasome.
Based on our current study and a previous report by Murakami et al.(Murakami et
al., 2012), it appears that calcium mobilization is a critical step during NLRP3
inflammasome activation. Calcium is a key signaling mediator for a number of cellular
proteases, protein kinases and phospholipases, some of which may be involved in NLRP3
inflammasome activation. Consistent with this notion, ERK1/2 kinase has been
implicated in regulating activation of the NLRP3 inflammasome(Cruz et al., 2007).
Similarly, we have preliminary data indicating that the inhibition of protein kinase C α
also partially impairs NLRP3 inflammasome activation (unpublished results). These
calcium-dependent enzymes may function to either proteolytically inactivate a negative
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regulator or activate a positive regulator of NLRP3, resulting in the assembly of the
inflammasome complex.
Finally, accumulating evidence has suggested that dysregulation of the NLRP3
inflammasome is tightly associated with many inflammatory disorders, such as gout,
atherosclerosis, silicosis, asbestosis, and Alzheimer’s disease(Davis et al., 2011; Strowig
et al., 2012). In this study, we demonstrated that TRPM2 deficiency drastically impairs
the inflammatory response induced by MSU crystals, the casual agent of gout. This
finding has therefore suggested a therapeutic potential of targeting TRPM2 to treat
NLRP3 inflammasome-associated autoinflammatory diseases. Furthermore, other studies
have also linked the NLRP3 inflammasome to a number of metabolic diseases, including
obesity and type 2 diabetes(Stienstra et al., 2010; Vandanmagsar et al., 2011; Wen et al.,
2011). For instance, NLRP3 deficiency protects mice from high-fat diet-induced obesity,
and the saturated fatty acid palmitate, which is found in high-fat diets, can induce NLRP3
inflammasome-mediated IL-1β secretion, which interferes with insulin signaling and
eventually results in reduced glucose tolerance and insulin sensitivity. Because our results
indicate a role for TRPM2 in NLRP3 inflammasome activation, blocking TRPM2 would
be expected to rescue metabolic disorders that are a result of a high-fat diet. In support of
this hypothesis, a recent study suggested that TRPM2-deficient mice have attenuated
obesity-mediated inflammation and that TRPM2 deletion can protect mice from
developing diet-induced obesity and insulin resistance(Zhang et al., 2012). Together,
these studies highlight the therapeutic potential of targeting TRPM2 to treat
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autoinflammatory and metabolic disorders associated with undesirable activation of the
NLRP3 inflammasome.
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